Form 4: Relay Therapeutics Grants Options to R&D President

Relay Therapeutics, Inc. granted 575,000 stock options to Donald A. Bergstrom, President of R&D, with an exercise price of $7.94.

Summary

• Donald A. Bergstrom, President of R&D at Relay Therapeutics, Inc. (RLAY), was granted 575,000 stock options.
• The options have an exercise price of $7.94 per share.
• The earliest transaction date for this grant was January 13, 2026.
• The shares underlying these stock options will vest in sixteen (16) equal quarterly installments after January 13, 2026.
• Vesting is contingent upon Mr. Bergstrom's continued service with the Issuer through each vesting date.
• The options have an expiration date of January 12, 2036.
• Following this transaction, Mr. Bergstrom beneficially owns 575,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation event (stock option grant) which is generally positive for executive retention and alignment of interests, but not a significant operational or financial announcement that would drastically change the company's outlook.

Positives

• The grant of stock options aligns the interests of a key executive, Donald A. Bergstrom (President, R&D), with long-term shareholder value.
• This compensation structure serves as an incentive for executive retention and performance over a multi-year period.

Future Outlook

The vesting schedule for the granted stock options extends over four years, indicating a long-term incentive structure for the President of R&D, contingent on continued service.

Industry Context

The grant of stock options to a senior executive is a common practice in the biotechnology and pharmaceutical industries. It is a standard mechanism to attract, retain, and motivate key talent, particularly in R&D-focused companies like Relay Therapeutics, by linking executive compensation to the company's long-term stock performance and strategic goals.

Comparison to Industry Standards

• Granting stock options to key executives, particularly in the biotechnology sector, is a common practice to incentivize long-term performance and retain talent.
• The size of the grant (575,000 options) and the vesting schedule (16 equal quarterly installments over 4 years) are within typical industry norms for a President-level executive in a growth-oriented company like Relay Therapeutics, Inc. (RLAY).

Related Party Transactions

• The grant of 575,000 stock options to Donald A. Bergstrom, President of R&D, constitutes a related party transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: Potential benefit from increased executive alignment with long-term company performance.
• Employees (specifically Donald A. Bergstrom): Receives significant equity compensation, incentivizing continued service and performance.

Next Steps

• The stock options will vest in sixteen equal quarterly installments after January 13, 2026, subject to continued service.

Key Dates

Recommendation

The Form 4 reports a routine stock option grant to a key executive, which is a standard compensation practice aimed at aligning management incentives with long-term shareholder value. This filing does not contain information that would significantly alter the investment thesis for Relay Therapeutics, thus a 'hold' recommendation is appropriate based solely on this document.

Keywords

Relay Therapeutics, RLAY, Stock Option, Insider Transaction, Form 4, Executive Compensation, Equity Grant, Donald A. Bergstrom